{"product_id":"scripps-cardiovascular-atherosclerosis-prediction-prevention-and-management-2025","title":"Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2025","description":"\u003ch3\u003eScripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2025\u003c\/h3\u003e\n\u003cstrong\u003e Include: 16 videos + 13 pdfs, size: 4.02 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eTarget Audience: cardiologists, internists, preventive medicine specialists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eCardiovascular Atherosclerosis: Prediction, Prevention and Management\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eMay 17, 2025 • San Diego Marriott • La Jolla, California\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eConference Overview\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eDespite notable advances in management, atherosclerotic cardiovascular disease (ASCVD) and its major clinical manifestations remains a leading cause of both morbidity and mortality worldwide.\u003cbr\u003e\u003cbr\u003eIn the United States alone, ASCVD is the leading cause of death in most racial and ethnic populations and is estimated to cost more than $200 billion per year due to medications, healthcare service utilization, and productivity losses. Many of these human and economic costs are largely attributable to poor implementation of prevention strategies in adults and failure to control ASCVD risk factors using available medications\u003cbr\u003eand lifestyle interventions. The Scripps Cardiovascular Atherosclerosis conference is designed to assist clinicians in the prevention, diagnosis, treatment, and ongoing management of ASCVD among patients in their clinical practices, as well as to promote increased awareness of prudent lifestyle and dietary choices to improve patient outcomes.\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eEducational Objectives\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003eAfter attending this live activity, participants should be able to:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eIdentify effective treatments, including lifestyle modifications, for managing atherosclerotic cardiovascular disease (ASCVD).\u003c\/li\u003e\n\u003cli\u003eEvaluate current guideline-directed medical therapy (GDMT) options and emerging strategies for managing cardiovascular disease.\u003c\/li\u003e\n\u003cli\u003eIdentify the unique risk factors, symptoms, and treatment considerations associated with cardiovascular disease in women.\u003c\/li\u003e\n\u003cli\u003eDescribe novel treatment approaches and assess the role of renal denervation in the management of treatment-resistant hypertension.\u003c\/li\u003e\n\u003cli\u003eIncorporate evidence-based practices in clinical settings for diagnosing, managing, and treating peripheral artery disease.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003eThe Scripps \u003cem\u003eCardiovascular Atherosclerosis: Prediction, Prevention and Management 2025\u003c\/em\u003e symposium is best for cardiologists, internists, preventive medicine specialists, and allied health professionals who want updates on risk assessment, prevention strategies, and management of atherosclerotic cardiovascular disease.\u003cbr\u003e\u003ch3\u003e👩‍⚕️ Who Should Attend\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eCardiologists (general and interventional) managing patients with coronary artery disease and vascular risk.\u003c\/li\u003e\n\u003cli\u003eInternists and family physicians providing frontline preventive care for cardiovascular disease.\u003c\/li\u003e\n\u003cli\u003ePreventive medicine specialists focusing on risk factor modification and population health.\u003c\/li\u003e\n\u003cli\u003eEndocrinologists managing diabetes and metabolic syndrome as major contributors to atherosclerosis.\u003c\/li\u003e\n\u003cli\u003eNurse practitioners, physician assistants, and pharmacists involved in cardiovascular risk management.\u003c\/li\u003e\n\u003cli\u003eResidents and fellows in cardiology or internal medicine preparing for board exams or subspecialty practice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003e📚 What You’ll Learn\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eRisk prediction tools: emerging biomarkers, imaging modalities, and genetic risk assessment.\u003c\/li\u003e\n\u003cli\u003ePrevention strategies: lifestyle interventions, lipid management, hypertension control, and diabetes care.\u003c\/li\u003e\n\u003cli\u003ePharmacologic therapies: statins, PCSK9 inhibitors, anti‑inflammatory agents, and novel drugs.\u003c\/li\u003e\n\u003cli\u003eManagement of established disease: secondary prevention, revascularization, and long‑term outcomes.\u003c\/li\u003e\n\u003cli\u003eCase‑based discussions: practical approaches to complex patients with multiple risk factors.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003eSaturday, May 17, 2025\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e6:45 a.m. Registration, Breakfast \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e7–7:55 a.m. Non-CME Breakfast Symposium Hosted by AstraZeneca\u003c\/li\u003e\n\u003cli\u003e7:55 a.m. Welcome \u0026amp; Introductions David Cork, MD and Christopher Suhar, MD\u003c\/li\u003e\n\u003cli\u003e8 a.m. LDL-Cholesterol: Ideal Targets. How Low is too Low? Nicholas Marston, MD\u003c\/li\u003e\n\u003cli\u003e8:30 a.m. Non-Statin Therapies: Deep Dive Pam Taub, MD\u003c\/li\u003e\n\u003cli\u003e9 a.m. Cardiometabolic Health: The Risk of Obesity and Pharmacotherapy Review Lauren Vincent, MD\u003c\/li\u003e\n\u003cli\u003e9:30 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e9:45 a.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e10:15 a.m. Resistant Hypertension Management: Current and Future Pharmacotherapies and Renal Denervation David Cork, MD\u003c\/li\u003e\n\u003cli\u003e10:45 a.m. Diagnostic Testing for Obstructive CAD: Which Modality to Choose? Matthew Budoff, MD\u003c\/li\u003e\n\u003cli\u003e11:15 a.m. Cardiovascular Disease in Women: An Update Martha Gulati, MD\u003c\/li\u003e\n\u003cli\u003e11:45 a.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eNoon Non-CME Lunch Symposium Hosted by Novartis Pharmaceuticals Little Particle, Big Impact: Exploring Lp(a) From a Perspective of a Patient With a Premature ASCVD Event Dan Luu, PharmD, BCPS\u003c\/li\u003e\n\u003cli\u003e1 p.m. Atrial Fibrillation Management: Introducing Pulsed Field Ablation Nicholas Olson, MD\u003c\/li\u003e\n\u003cli\u003e1:30 p.m. Atrial Fibrillation Management: Anticoagulation or Left Atrial Appendage Occlusion? Douglas Gibson, MD\u003c\/li\u003e\n\u003cli\u003e2 p.m. Diet and Exercise: Counsel Your Patients More Effectively Christopher Suhar, MD\u003c\/li\u003e\n\u003cli\u003e2:30 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e2:45 p.m. Break \u0026amp; View Exhibits\u003c\/li\u003e\n\u003cli\u003e3 p.m. The Best Biomarkers to Assess Atherosclerotic Risk P. Barton Duell, MD\u003c\/li\u003e\n\u003cli\u003e3:30 p.m. Peripheral Artery Disease Update Curtiss Stinis, MD\u003c\/li\u003e\n\u003cli\u003e4 p.m. Diagnostic Evaluation and Management of Coronary Vasospasm and Endothelial Dysfunction Matthew Price, MD\u003c\/li\u003e\n\u003cli\u003e4:30 p.m. Panel Discussion\/Q\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e4:45 p.m. Adjourn Topics, times, and speakers are subject to change.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954518888546,"sku":"MED-AMB05166","price":50.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Scripps-Cardiovascular-Atherosclerosis-Prediction-Prevention-and-Management-2025.jpg?v=1779378735","url":"https:\/\/meducourse.com\/products\/scripps-cardiovascular-atherosclerosis-prediction-prevention-and-management-2025","provider":"Meducourse","version":"1.0","type":"link"}